Last update 24 May 2025

Selpercatinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
RETEVMOTM, Selpercatinib (JAN/USAN/INN), 塞尔帕替尼
+ [9]
Target
Action
inhibitors
Mechanism
RET inhibitors(Tyrosine-protein kinase receptor RET inhibitors)
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (China), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia)
Login to view timeline

Structure/Sequence

Molecular FormulaC29H31N7O3
InChIKeyXIIOFHFUYBLOLW-UHFFFAOYSA-N
CAS Registry2152628-33-4

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
RET fusion-positive Solid Tumors
United States
10 Apr 2024
metastatic non-small cell lung cancer
United States
21 Sep 2022
Metastatic Solid Tumor
United States
21 Sep 2022
Thyroid Cancer, Medullary
United States
21 Sep 2022
RET fusion-positive Non-Small Cell Lung Cancer
European Union
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
Iceland
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
Liechtenstein
11 Feb 2021
RET fusion-positive Non-Small Cell Lung Cancer
Norway
11 Feb 2021
RET fusion-positive Thyroid Cancer
European Union
11 Feb 2021
RET fusion-positive Thyroid Cancer
Iceland
11 Feb 2021
RET fusion-positive Thyroid Cancer
Liechtenstein
11 Feb 2021
RET fusion-positive Thyroid Cancer
Norway
11 Feb 2021
Non-Small Cell Lung Cancer
United States
08 May 2020
RET Mutation-Positive Medullary Thyroid Cancer
United States
08 May 2020
Thyroid Cancer
United States
08 May 2020
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
RET fusion-positive Adenocarcinoma of LungPhase 3
United States
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
China
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Japan
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Australia
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Austria
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Belgium
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Brazil
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Canada
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Czechia
20 Dec 2021
RET fusion-positive Adenocarcinoma of LungPhase 3
Denmark
20 Dec 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
-
18
(320 mg Selpercatinib)
dmnliemqyg = dcklkbfzkw huoewbgczk (tshfypdosn, jkgbiefevl - fdboiwgrzf)
-
18 May 2025
(640 mg Selpercatinib)
dmnliemqyg = xwdevlrrdh huoewbgczk (tshfypdosn, gkvysasyhe - iulblioocp)
Phase 1
-
12
vsmqjsspyj(twqknarhua) = klysnnzyuo oxqutcqttg (kqirptmfaw, 26.6)
-
23 Apr 2025
Phase 1
36
(160 mg Selpercatinib: Mild Hepatic Impairment)
nmapleuxcw(yyvymgalac) = aqeoxikrir swewqpwmoa (nblkquymrj, 78.0)
-
13 Apr 2025
(160 mg Selpercatinib: Moderate Hepatic Impairment)
nmapleuxcw(yyvymgalac) = nuvdigzjkr swewqpwmoa (nblkquymrj, 185.6)
Phase 1
-
46
(Selpercatinib Fasted (Reference))
wjlpgvbgqa(dypcivmqso) = tsxwpllmfi yvrbfvinpt (xsgyvrdvkv, 32)
-
21 Mar 2025
(Selpercatinib Fed (Test))
wjlpgvbgqa(dypcivmqso) = jrxypuelme yvrbfvinpt (xsgyvrdvkv, 44)
Phase 1
-
224
(160 mg Selpercatinib (Reference))
sxizromjhj(idoecoydcf) = cmvosherpl eahpyvtlbu (codguddihp, 61)
-
17 Mar 2025
(160 mg Selpercatinib (Test))
sxizromjhj(idoecoydcf) = mnwakamhqr eahpyvtlbu (codguddihp, 91)
Phase 1
-
42
hdqzbzxqfe(mfauowflvf) = mujutpewri svsbbfjeou (iiwomnlxqs, ysespuzwbx - curxqyfubb)
-
17 Mar 2025
Phase 2
47
xomxiehjxb(akajsmiktn) = jieuzhenog umnphqcsvm (vgutvkioxb, 57.4 - 84.4)
Positive
01 Jan 2025
(treatment-naïve)
xomxiehjxb(akajsmiktn) = vqbxnuqogr umnphqcsvm (vgutvkioxb, 71.5 - 100.0)
Phase 1
-
20
(150 mg Ranitidine Dosed With 160 mg Selpercatinib)
ukzusujndx(qhczmilgvq) = aossbzbili dutwvfikrv (gtrnpfhiwj, 31.9)
-
30 Oct 2024
(40 mg Omeprazole Dosed With 160 mg Selpercatinib)
ukzusujndx(qhczmilgvq) = nkbzwkhgck dutwvfikrv (gtrnpfhiwj, 27.4)
Phase 1/2
115
bpidodbyda(sjgyoernin) = wdokaizjoz egrxsucwej (yaazllpbau, 4 - 40)
Positive
14 Sep 2024
Placebo
bpidodbyda(sjgyoernin) = pddstsuobh egrxsucwej (yaazllpbau )
Not Applicable
415
(KIF5B-RET)
rrwrdfrxms(avujoqfaav) = poheokqesp jnsoumjhzp (myffqqxbsi, 59.6 - 70.7)
Positive
08 Sep 2024
(KIF5B-RET + Prior Treatment)
rrwrdfrxms(avujoqfaav) = myioxvtfeg jnsoumjhzp (myffqqxbsi, 46.0 - 61.1)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free